Tumor Mutational Burden (TMB) Assay for Response to Immunotherapy

TMB assay utilizing whole exome sequencing (WES) methodology and proprietary variant analysis compendium

Tumor Mutational Burden (TMB) is a putative biomarker of response to checkpoint inhibitor therapy. Q2 Solutions offers a TMB assay that utilizes a whole exome sequencing (WES) of tumor specimens for reliable quantification of TMB across various tumor indications. 

Learn more about our TMB assay specifications and our comprehensive portfolio of genomic assays for immuno-oncology applications.